Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort

NCT07131878 | Not Yet Recruiting DMC

• 1 other identifier: Aquired Aplastic Anemia ttt
• Study Type: observational
• Target: 35
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children

Conditions

Aplastic Anaemia (AA)

Outcome Measures

Primary Outcomes (1)

• To evaluate the treatment outcomes of children diagnosed with aplastic anemia.

  July 2023-July 2026

Secondary Outcomes (1)

• To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only

  July 2023_July 2026

Study Arms (2)

patient diagnosed with aplastic anemia from July 2023 to sept 2025

patient diagnosed with aplastic anemia from Sept 2025 to July 2026

Eligibility Criteria

• Age: 1 Year - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Children aged 1-18 years diagnosed with acquired aplastic anemia

You may qualify if:

• Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity \<25% and at least two of the following: absolute neutrophil count \<500/μL, platelet count \<20,000/μL, absolute reticulocyte count \<60,000/μL)123.
• The bone marrow biopsy should be compitable with diagnosis
• Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
• Patients with complete medical records, including diagnostic, laboratory, and treatment data

You may not qualify if:

• Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
• Patients with incomplete or missing essential data in their medical records.
• Patients diagnosed outside the specified study period or managed primarily at other institutions.
• Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
• Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Anemia, Aplastic

Condition Hierarchy (Ancestors)

Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Bone Marrow Failure Disorders; Bone Marrow Diseases

Central Study Contacts

Marwa M Abozaid, master

CONTACT

+201146679786; marwaabozaid39@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident doctor

Study Record Dates

• First Submitted: August 13, 2025
• First Posted: August 20, 2025
• Study Start: September 15, 2025
• Primary Completion (Estimated): September 15, 2027
• Study Completion (Estimated): January 15, 2028
• Last Updated: August 20, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share